News on immunohistochemistry and other tissue-based testing methods.
The company's approach involves using both fluorescence in situ hybridization and next-generation sequencing to provide clinicians with information.
The company said the financing brings it a step closer to fulfilling its vision of enabling new-generation tissue analytics tests based on its microfluidic technology.
Abbott highlighted its next-generation Alinity platforms, and Caris discussed its plans to provide precision oncology services.
The firm said that the new financing will help it accelerate commercial initiatives in the US, Europe, Brazil, and Canada.
The company has multiple companion diagnostics partnerships in the works, with new tests on the way in 2020, and new plans for next-generation sequencing.
